08 Nov The risk of acute tubulointerstitial nephritis (TIN) associated with proton pump inhibitors (PPIs)
Posted at 13:33h
in
The Pharmaceutical Companies listed above, as directed by the South African Health Products Regulatory Authority (SAHPRA), would like to update you on the safety information regarding acute tubulointerstitial nephritis (TIN) that has been observed with the use of Pantoloc® / Topzole® (Pantoprazole), Dexilant® (Dexlansoprazole), Nexiam® / Axiago® (esomeprazole) and Pariet® (rabeprazole). TIN is a recognized adverse drug reaction for these drugs (see Side Effects section of respective Professional Information).
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
30/10/2023
File Type:
pdf
Category:
Communication To Health Care Professionals